Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy |
Taguchi, Satoru
(Department of Urology, Graduate School of Medicine, The University of Tokyo)
Fukuhara, Hiroshi (Department of Urology, Graduate School of Medicine, The University of Tokyo) Kakutani, Shigenori (Department of Urology, Graduate School of Medicine, The University of Tokyo) Takeshima, Yuta (Department of Urology, Graduate School of Medicine, The University of Tokyo) Miyazaki, Hideyo (Department of Urology, Graduate School of Medicine, The University of Tokyo) Suzuki, Motofumi (Department of Urology, Graduate School of Medicine, The University of Tokyo) Fujimura, Tetsuya (Department of Urology, Graduate School of Medicine, The University of Tokyo) Nakagawa, Tohru (Department of Urology, Graduate School of Medicine, The University of Tokyo) Igawa, Yasuhiko (Department of Urology, Graduate School of Medicine, The University of Tokyo) Kume, Haruki (Department of Urology, Graduate School of Medicine, The University of Tokyo) Homma, Yukio (Department of Urology, Graduate School of Medicine, The University of Tokyo) |
1 | Abdollah F, Karnes RJ, Suardi N, et al (2014). Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol, 65, 554-62. DOI |
2 |
Akaza H, Cheng JC, Chung BH, et al (2013). NCCN clinical practice guidelines in oncology (NCCN |
3 | Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA (2006). Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol, 176, 564-8. DOI |
4 | D'Amico AV, Whittington R, Malkowicz SB, et al (1998). Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280, 969-74. DOI |
5 | Dorff TB, Flaig TW, Tangen CM, et al (2011). Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol, 29, 2040-5. DOI |
6 | Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: Intl Agency Res Cancer. Available from: http://globocan.iarc.fr, accessed on day/month/year. |
7 | Jackson W, Hamstra DA, Johnson S, et al (2013). Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 119, 3287-94. DOI |
8 | Matsuda A, Matsuda T, Shibata A, et al (2014). The Japan cancer surveillance research group. cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) Project. Jpn J Clin Oncol, [E-pub ahead of print]. |
9 | McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13. DOI ScienceOn |
10 | Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8. DOI |
11 | Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG (2002). Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int, 89, 604-11. DOI |
12 | Messing EM, Manola J, Yao J, et al (2006). Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol, 7, 472-9. DOI |
13 | Mohler J, Bahnson RR, Boston B, et al (2010). NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw, 8, 162-200. |
14 | Nguyen CT, Reuther AM, Stephenson AJ, Klein EA, Jones JS (2009). The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol, 181, 75-80. |
15 | Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004). Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol, 172, 910-4. DOI |
16 | Ryan CJ, Small EJ (2005). Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol, 23, 8225-31. DOI |
17 | Sato YT, Fukuhara H, Suzuki M, et al (2014). Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol, 14, 13. DOI |
18 | Situmorang GR, Umbas R, Mochtar CA, et al (2012). Prostate cancer in younger and older patients: do we treat them differently? Asian Pac J Cancer Prev, 13, 4577-80. DOI ScienceOn |
19 | Sundi D, Wang VM, Pierorazio PM, et al (2014). Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis, 17, 57-63. DOI |
20 | Taguchi S, Fujimura T, Kume H, Homma Y (2012). Zoledronic acid administration in aggressive castration-resistant prostate cancer. Asian Pac J Cancer Prev, 13, 6539-40. DOI |
![]() |